Related Experiment Video

Updated: Aug 28, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The new "lower is better" lipid goals: are they achievable with today's drugs?

Robert J Chilton1

  • 1Division of Cardiology at the University of Texas Health Science Center at San Antonio, 78261-9521, USA. chilton@uthscsa.edu

The Journal of the American Osteopathic Association
|June 6, 2002
PubMed

Insights

Lowering low-density lipoprotein cholesterol (LDL-C) with statins reduces coronary heart disease (CHD) risk. Statins offer additional benefits beyond lipid reduction, including anti-inflammatory and anti-thrombotic effects for comprehensive cardiovascular protection.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Current guidelines recommend lowering low-density lipoprotein cholesterol (LDL-C) to below 100 mg/dL to reduce coronary heart disease (CHD) risk.
  • Acute coronary events are influenced by lipid levels and inflammatory processes that can lead to plaque rupture.

Purpose of the Study:

  • To evaluate the role of statin therapy in managing LDL-C levels and mitigating coronary heart disease (CHD) risk.
  • To explore the pleiotropic effects of statins beyond lipid-lowering.

Main Methods:

  • Review of Adult Treatment Panel (ATP III) guidelines and prospective trial data.
  • Analysis of research on statin mechanisms of action, including anti-inflammatory and anti-thrombotic effects.

Main Results:

  • Statin therapy effectively lowers LDL-C to target levels, with newer formulations offering greater reductions.
  • Statins demonstrate pleiotropic effects: reducing inflammation, counteracting thrombosis, improving endothelial function, inhibiting plaque progression, and promoting angiogenesis.

Conclusions:

  • Comprehensive risk reduction strategies, including statins, diet, exercise, and weight management, are crucial for minimizing CHD events.
  • Statins provide multifaceted cardiovascular benefits by addressing both lipid levels and inflammatory pathways involved in atherosclerosis.

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...